A clinical trial flop doesn't leave the biotech a lot of options.
News & Analysis: AnaptysBio
Investors have lost faith in the biopharma, which is sitting at its lowest market cap in two years. But Wall Street may be overlooking a significant catalyst from a partnered asset.
The company released some positive data yesterday...that wasn't positive enough.
An executive's departure at a sensitive time has investors nervous.
During the second quarter, the company upgraded the safety net under its lead candidate.
A potential competitor stumbled in a midstage asthma trial.
The clinical-stage biotech hardly made a sound during the first three months of the year
Fourth-quarter progress set the biotech up with several new paths to success.
The clinical-stage biotech stock slid despite a third-quarter report that didn't contain any surprises.
The clinical-stage biotech's third-quarter report contained some important pipeline updates.